Abstract:Abstract Background / Objectives: A novel long-term animal model for human Graves’ disease (GD) was recently established in mice (Endocrinology 2015; 156: 1577-1589) using nine immunizations with recombinant adenovirus (Ad) expressing the extracellular A-subunit of the human thyrotropin receptor (TSHR) over 10 months. The aim of the present study is to detect and measure TSHR-Ab in the animal model of Ad-TSHR immunized mice. Methods: Female BALB/c mice received either 1010 plaque-forming units of adenovirus carrying the A-subunit of the TSHR gene or the green fluorescent protein (GFP) gene (injected into the femoral muscles). In addition, age-matched immunologically naïve mice were studied. Blood was withdrawn out of the left or right tail vein or intracardially (end of the study). The study protocol used three three-weekly immunizations (initiation), followed by a maintenance phase with further regular four-weekly boosts until the ninth immunization. Serum TSHR stimulating (TSAb) and -blocking (TBAb) Ab were measured with reporter bioassays. TSAb was reported as percentage of specimen-to-reference ratio (cut-off SRR% <140). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine TSH alone (% inhibition <34). Results: A total of twenty-two BALB/c mice were studied (ten, eight, and four Ad-TSHR, control, and Ad-GFP-immunized mice, respectively). All twelve control- and Ad-GFP-immunized mice were negative for both thyrotropin-binding inhibitory immunoglobulins (TBII) as well as for TSAb and TBAb measured with the cell-based bioassays. In contrast, baseline TBII were highly positive in all Ad-TSHR-immunized mice (median 40 IU/L, 25%-75% percentiles 40-40 IU/L, normal cut-off 0.55 IU/L) All these mice also developed hyperthyroidism with elevated free T4 (fT4) levels (median 4.5 ng/dl, 25-75 percentile 4.1-6 ng/dl; normal range 0.9-1.8 ng/dl). All control (0.1, 0.1-0.1 IU/L) and Ad-GFP-immunized (0.2, 0.1-0.3 IU/L) mice were TBII negative and the corresponding fT4 levels were 2.2 ng/dl (2.1-2.4 ng/dl) and 2 ng/dl (1.9-2.1 ng/dl), respectively (p<0.001 for both TBII and fT4 versus Ad-TSHR mice). The serum positivity for TSAb and TBAb in a total of 28 consecutive samples obtained from ten Ad-TSHR mice was 12 (43%) and 21 (75%), respectively. Especially, serum samples of two (20%) Ad-TSHR mice were highly positive in the TSAb bioassay only with a SRR% value of 397 (329-465, p<0.001 vs. control mice). In comparison, sera of four Ad-TSHR mice (40%) were highly positive when measured with the TBAb bioassay only showing a % inhibition value of 69 (63-76). Furthermore, serum samples of four Ad-TSHR mice (40%) demonstrated dual TSAb/TBAb positivity. Conclusions: Functional TSHR-Ab are highly prevalent in Ad-TSHR immunized mice, thus confirming the successful establishment of a novel, long-term animal model for GD.

Role Of Natural Killer T Cells In Graves' Disease

The levels of TSH receptor antibodies in the serum of natural killer T cells in deficient mice with Graves'-like disease

Impairment of Regulatory Capacity of Cd4(+)Cd25(+) Regulatory T Cells Mediated by Dendritic Cell Polarization and Hyperthyroidism in Graves' Disease

THE EFFECT OF FCγ RECEPTOR ON THE PATHOGENESIS OF GRAVES＇ DISEASE

The Significance Of Immune-Related Molecule Expression Profiles In An Animal Model Of Graves' Disease

Natural Killer Cells Modulate Overt Autoimmunity to Homeostasis in Nonobese Diabetic Mice after Anti-CD3 F(ab′)2 Antibody Treatment through Secreting Transforming Growth Factor-β

Natural killer cells promote the differentiation of follicular helper T cells instead of inducing apoptosis in myasthenia gravis

The Role of Natural Killer Cells in Autoimmune Diseases

Plasmacytoid dendritic cells,interferon-α and CD4~+ CD25~+ regulatory T cells in immunopathogenic mechanism of Graves disease

Low frequency of IL-10-producing B cells and high density of ILC2s contribute to the pathological process in Graves’ disease, which may be related to elevated-TRAb levels

Expression of IFNα-inducible Genes and Modulation of HLA-DR and Thyroid Stimulating Hormone Receptors in Graves’ Disease

The relationship between CD4~+ CD25~+ regulatory T cell and Graves' disease

Study on Induction of Immunotolerance Against Graves' Disease in Neonatal Mice

Increased Proportions of Tc17 Cells and NK Cells May Be Risk Factors for Disease Progression in Hashimoto's Thyroiditis.

Immunoregulatory natural killer cells

Implications for the Immune–Endocrine Interaction

Absolute reduction in peripheral regulatory T cells in patients with Graves’ disease and post-treatment recovery

The Immune Responses in Graves' Disease Mouse Model As Investigated Through Synthetic Linear Peptides

Studies on the development of a mouse model of Graves' disease

SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model

Ablation of NK Cell Function During Tumor Growth Favors Type 2-Associated Macrophages, Leading to Suppressed CTL Generation